Updated time: 2023-09-05 16:18:52
28A-1090526
2021-02-24
TW I811957、USP Pending.
Our invention is a conjugate vaccine which compose of multiple synthetic peptide ,with their sequence modified from a region that had been proved vital to IL-17RB signaling transduction, cross linked to a non-toxic carrier protein CRM197 which possess high immunostimulant property, by cross-linker SBAP. Animal model shows that immune response elicited by this vaccine mitigate metastasis rate of cancer cells that are otherwise highly metastatic.
Our invention guarantee effective immune response against IL-17RB, thus are ideal for anti-IL-17RB monoclonal antibody preparation.
- Anti-cancer therapy: This invention can be used alongside current anti-cancer regimen to enhance prognosis and long-term survival.
- Generating monoclonal antibody: Conventional way of generating monoclonal antibody suffers from sub-dominal immunogenicity of interested region.
Che Ma, Wen-Hwa Lee, Tracer Yong
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

RECOMBINANT POLYPEPTIDES, CONJUGATES COMPRISING THE SAME, AND USES THEREOF